Vulvar Lichen Sclerosus
Chronic inflammatory vulvar dermatosis with porcelain-white plaques and architectural change.
Also known as: lichen sclerosus, LS, vulvar lichen sclerosus, kraurosis vulvae
Overview
Chronic, relapsing inflammatory dermatosis predominantly affecting the anogenital skin, characterized by thinning, depigmentation, and architectural destruction. Carries an increased lifetime risk of vulvar squamous cell carcinoma (up to about 5%), which adherent long-term treatment appears to lower.
Epidemiology
Bimodal distribution: prepubertal girls and postmenopausal women, with peak incidence in the 6th-7th decade. Female-to-male ratio ~10:1.
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Vulvar Lichen Sclerosus outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Risk factors
- Autoimmune comorbidity (thyroid disease, vitiligo, pernicious anemia, alopecia areata, type 1 DM)
- Family history of LS
- Possible role of chronic occlusion, irritation, and Koebner phenomenon
Pathophysiology
Autoimmune process with T-cell-mediated injury to basal keratinocytes producing characteristic histology of hyperkeratosis, epidermal atrophy, basement membrane thickening, and a homogenous band of hyalinized collagen in the upper dermis with a lichenoid lymphocytic infiltrate beneath.
Clinical presentation
Symptoms
- Severe vulvar and perianal pruritus (most common; often worse at night)
- Burning, soreness, dyspareunia
- Dysuria, urinary symptoms
- Dyschezia and constipation if perianal involvement
- Children may present with constipation, dysuria, or behavioral changes; itching and visible findings may be missed
Signs / physical exam
- Porcelain-white, atrophic, crinkly ('cigarette-paper') plaques on labia minora, clitoral hood, and perianal area in a classic 'figure-of-8' or 'keyhole' distribution sparing the vagina
- Architectural change: resorption of labia minora, fusion of clitoral hood, narrowing of introitus
- Ecchymoses, fissures, and erosions are common
- Lichenification from scratching
Differential diagnosis
- Lichen planus — Erosive lesions, oral involvement, Wickham striae, more commonly with painful erosions and dyspareunia
- Lichen simplex chronicus — Thickened, leathery skin from chronic rubbing; pruritus prominent, architecture preserved
- Vitiligo — Symmetric depigmentation without atrophy or architectural change
- Atrophic vaginitis — Hypoestrogenic changes, no architectural destruction or porcelain plaques
- Vulvar intraepithelial neoplasia (VIN) / SCC — Persistent plaque, ulcer, or mass — biopsy any non-responding or atypical lesion
- Sexual abuse (pediatric) — LS can mimic with subepithelial hemorrhage; both require careful evaluation
Diagnostic workup
Diagnostic criteria
Clinical with characteristic appearance is usually sufficient. Punch biopsy is recommended for atypical features, treatment failure, or suspicion of malignancy.
Labs
- TSH (associated thyroid autoimmunity)
- Glucose if symptomatic
- No routine serologies otherwise
Imaging
- Not routinely indicated
Diagnostic algorithm
| Feature | Lichen Sclerosus | Lichen Planus | Lichen Simplex Chronicus |
|---|---|---|---|
| Typical location | Vulva, perianal (figure-of-8), not vaginal | Vulva, vagina, oral mucosa | Wherever scratched (often labia majora) |
| Appearance | White, atrophic, 'cigarette-paper' skin | Erosive, Wickham striae, painful | Thick, leathery, lichenified |
| Architecture | Resorbed labia minora, phimosis | Vaginal adhesions, synechiae | Preserved |
| First-line tx | Ultrapotent topical steroid (clobetasol) | Ultrapotent topical steroid | Mid-potency steroid + break itch-scratch cycle |
Treatment
First-line
- Ultrapotent topical corticosteroid — clobetasol propionate 0.05% ointment is the gold standard
- Typical regimen: nightly for 4 weeks, every other night for 4 weeks, twice weekly for 4 weeks, then maintenance 1-2 times weekly indefinitely
- Emollients (white petrolatum, zinc oxide) and irritant avoidance (no soaps, fragranced products, tight clothing)
- Treatment continues indefinitely — LS is chronic and requires maintenance to prevent flares and malignant transformation
- Follow up every 6-12 months for assessment of response and surveillance for malignancy
Second-line / adjunct
- Topical calcineurin inhibitors (tacrolimus 0.1% ointment, pimecrolimus 1% cream) — second-line; useful in steroid-resistant or maintenance therapy; FDA black-box warning for theoretical malignancy risk
- Intralesional triamcinolone for refractory areas
- Topical or systemic retinoids in select cases
- Surgery limited to release of agglutination causing functional impairment, treatment of suspected malignancy, or vulvar cancer; surgical excision alone does not cure LS
Complications
- Vulvar squamous cell carcinoma (lifetime risk up to about 5%; usually HPV-independent, arising through differentiated VIN rather than HPV-associated vulvar HSIL)
- Architectural distortion: labial resorption, clitoral phimosis, introital stenosis
- Sexual dysfunction, dyspareunia
- Psychological impact: depression, anxiety
- Adhesions causing urinary obstruction in advanced disease
PANCE pearls
- Ultrapotent topical steroids are SAFE for long-term use on vulvar skin — undertreatment is far more harmful than steroid side effects.
- Always biopsy a non-responding, ulcerated, hyperkeratotic, or persistent plaque on lichen sclerosus skin — vulvar SCC arises in this background.
- LS spares the vagina; if vaginal involvement is present, consider lichen planus.
- Pediatric LS does not reliably resolve at puberty (it persists in many girls after menarche); treat it to prevent architectural change and keep monitoring through and after puberty.
- Topical estrogen does NOT treat LS and may delay diagnosis if used empirically — biopsy and steroids are the foundation.
- Vulvar SCC has two precursor pathways: HPV-associated vulvar HSIL (formerly usual-type VIN; younger women, smoking, immunosuppression, often multifocal, warty or basaloid) and HPV-independent differentiated VIN (dVIN; older women with lichen sclerosus or, less often, lichen planus; TP53 mutation; subtle and often unifocal; progresses to invasion more often and faster). Most LS-associated SCC arises through dVIN, so keep patients on maintenance clobetasol and in lifelong surveillance.
References
- ACOG PB 224 — ACOG Practice Bulletin No. 224: Diagnosis and Management of Vulvar Skin Disorders (Obstet Gynecol 2020)
- BAD 2018 — British Association of Dermatologists Guidelines for Lichen Sclerosus (Lewis et al., 2018)
- ISSVD — International Society for the Study of Vulvovaginal Disease terminology
- ACOG CO 675 — ACOG Committee Opinion No. 675: Management of Vulvar Intraepithelial Neoplasia (Obstet Gynecol 2016)
Practice Reproductive questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Start your 7-day free trial → Get today's free question →Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.